Lublin

• Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE2) Ended
  2022-502000-73-00 5 2023-08-11 Focal Onset Seizures
• A study evaluating the effects of GLPG3667 given as oral treatment for up to 24 weeks in adults with dermatomyositis Ended
  2022-501097-19-00 4 2023-08-09 dermatomyositis
• A Study to Evaluate the Efficacy and Safety of Astegolimab in Patients with Chronic Obstructive Pulmonary Disease Ended
  2022-502234-70-00 5 2023-07-14 Chronic Obstructive Pulmonary Disease (COPD)
• A multicentre, single arm trial on contraceptive efficacy, safety and tolerability of LVDS (Levonorgestrel Vaginal Delivery System) during 1 … Ended
  2022-502023-21-00 5 2023-07-12 Prevention of pregnancy
• A pivotal, multicentre, randomised, open-label, parallel-group trial on contraceptive efficacy, safety and tolerability of LVDS (Levonorgest … Ended
  2022-502024-51-00 5 2023-07-12 Prevention of pregnancy
• Phase 2b Study to Assess Efficacy and Safety of Batoclimab in Adult Participants with Active CIDP. Ended
  2024-512646-42-00 4 2023-06-27 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
• A trial to learn how well REGN9933 works for preventing blood clots after knee replacement surgery in adult participants Ended
  2022-501470-18-00 4 2023-06-26 Thromboembolic disease
• Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA) Ended
  2024-512554-15-00 5 2023-06-21 COVID-19
• A Study of Suvecaltamide in Adults with Moderate to Severe Residual Tremor in Parkinson's Disease Ended
  2024-515177-94-00 4 2023-06-21 Parkinson's Disease
• ABTECT-2 – ABX464 Treatment Evaluation for ulcerative Colitis Therapy -2 Ended
  2022-500536-11-01 5 2023-06-08 Moderately to severely active ulcerative colitis
• Efficacy, Safety, Tolerability Study of LYR-210 Depot in Chronic Sinusitis Ended
  2023-506268-15-00 5 2023-06-05 Chronic Rhinosinusitis (CRS) in Adults
• A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (S … Ended
  2022-501753-36-00 5 2023-06-02 Hidradenitis Suppurativa
• A 2-year Open-label Extension Study to Assess the Long-term Safety and Efficacy of Lebrikizumab in Adult and Adolescent Patients with Modera … Ended
  2022-502575-30-00 5 2023-05-23 Atopic Dermatitis
• A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemia Ended
  2022-501420-20-00 5 2023-05-17 Severe hypertryglyceridemia
• A Study of Two Dose Levels of Vobramitamab Duocarmazine in Participants with Metastatic Castration-resistant Prostate Cancer (TAMARACK) Ended
  2022-501078-20-00 4 2023-05-15 Metastatic Castration-resistant Prostate Cancer
• Phase 3, 52-week Study Evaluating Rocatinlimab (AMG451)in Adolescent Subjects With Moderate-to-severe AD (ROCKET-ASTRO) Ended
  2022-501586-50-00 5 2023-05-15 Atopic Dermatitis
• Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of VE202 in Patients with Mild-to-Moderate Ulcerative Colitis Ended
  2024-512558-40-00 4 2023-05-11 Mild-to-moderate ulcerative colitis
• A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe AD (ROCKET-Horizon) Ended
  2022-501538-44-00 5 2023-04-25 Atopic Dermatitis
• A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab Monotherapy in Moderate-to-severe AD (ROCKET-Ignite) Ended
  2022-501540-15-00 5 2023-04-25 Atopic Dermatitis
• A 52-week Clinical Trial to Study the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-2) Ended
  2023-507665-25-00 5 2023-04-25 Severe Eosinophilic asthma
• A 24-week Clinical Trial to Study the Effect of Dexpramipexole in Adolescents and Adults With Eosinophilic Asthma (EXHALE-4) Ended
  2023-509739-22-00 5 2023-04-25 Eosinophilic asthma
• A Study to Investigate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of RO7200220 Administered Intravitreally in Patients wit … Ended
  2022-501793-19-00 5 2023-04-21 Uveitic Macular Edema
• Long-term Efficacy and Safety of Tozorakimab in Participants with Chronic Obstructive Pulmonary Disease with a History of Exacerbations. Ended
  2022-501063-41-00 5 2023-04-20 Chronic Obstructive Pulmonary Disease (COPD)
• Protocol Lay Person Short Title: A Trial of the Safety and Efficacy of Flexible Doses of SEP-363856 as Adjunctive Therapy in the Treatment o … Ended
  2022-500538-27-00 10 2023-03-30 Adjunctive therapy to antidepressants for the treatment of major depr

Showing 673–696 of 786 trials